Clinical Trials · NCT03448744
Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients
- Phase
- Phase 4
- Recruitment status
- Unknown
- Sponsor
- Wen-hong Zhang
- Enrollment
- 240
- Start date
- Oct 2017
- Locations
- 1 site, China
- Primary endpoint
- HBeAg seroconversion rate at week 72